HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 92.8%

Neg 0% Neu 92.8% Pos 0%

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.